Trial Profile

A Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Tislelizumab + Chemotherapy Followed by Adjuvant Tislelizumab for the Treatment of Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Jun 2024 An interim results assessing the efficacy and safety of tislelizumab plus IC, followed by CCRT and adjuvant tislelizumab therapy in pwith locoregionally advanced nasopharyngeal carcinoma were presented at the 60th Annual Meeting of the American Society of Clinical Oncology
16 Apr 2024 Planned End Date changed from 25 Mar 2027 to 30 May 2028.
16 Apr 2024 Planned primary completion date changed from 25 Mar 2024 to 30 May 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com